Drug Interactions of Tipranavir, a New HIV Protease Inhibitor

Authors: Morello, Judit; Rodriguez-Novoa, Sonia; Jimenez-Nacher, Inmaculada; Soriano, Vincent

Source: Drug Metabolism Letters, Volume 1, Number 1, January 2007 , pp. 81-84(4)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $62.88 plus tax (Refund Policy)

Abstract:

Tipranavir is one of the latest approved HIV protease inhibitors. This non-peptidic molecule is an strong inducer of cytochrome P450 and has to be co-administered with low doses ritonavir as pharmacokinetic booster to achieve effective antiviral activity in vivo. As expected, significant drug interactions may occur in patients treated with tipranavir/ ritonavir, including diminished exposure to some antiretroviral agents. Although a few interactions can be managed with adequate drug dosing others preclude to use these medications in combination.

Keywords: Tipranavir; HIV; drug interactions; protease inhibitors

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187231207779814256

Affiliations: 1: Department of Infectious Diseases,Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain.

Publication date: 2007-01-01

More about this publication?

Drug Metabolism Letters publishes short papers on major advances in all areas of drug metabolism and disposition. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of the Internet technology for both the submission and review of manuscripts. The journal covers the following areas:

In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites, reactive intermediate and glutathione conjugates.